CompletedInterventionalPhase 3Last updated Dec 6, 2024

Efficacy and Safety Study of SAL-0951 in the Treatment of Renal Anemia in Patients Receiving Peritoneal Dialysis

A Phase III, Multicenter, Open-label, Single-arm Clinical Study to Evaluate the Efficacy and Safety of SAL-0951 Tablets in the Treatment of Renal Anemia in Patients With Chronic Kidney Disease Receiving Maintenance Peritoneal Dialysis

Overview

ClinicalTrials.gov ID: NCT06720233
Lead Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.INDUSTRY
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of SAL-0951 in Chinese patients receiving peritoneal dialysis with chronic kidney disease and anemia
Study Type: Interventional

Status

Overall Status: Completed
Start Date: Feb 22, 2002Actual
Primary Completion Date: Oct 18, 2024Actual
Completion Date: Oct 28, 2024Actual

Study Record Dates

First Submitted: Dec 2, 2024
First Submitted that Met QC Criteria: Dec 2, 2024
First Posted: Dec 6, 2024Actual
Last Update Submitted that Met QC Criteria: Dec 2, 2024
Last Update Posted: Dec 6, 2024Actual
Last Verified: Dec 2024

NCT06016036Completed

SAL-0951 Tablets in the Treatment of Renal Anemia in Non-dialysis Chronic Kidney Disease

NCT06720025Completed

Study of SAL-0951 Compared to Recombinant Human Erythropoietin in Anemic Patients Receiving Maintenance Hemodialysis

NCT07647133Not yet recruiting

A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Chronic Kidney Disease

NCT06737081Recruiting

SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies

NCT07716618Active, not recruiting

A Phase II Clinical Trial of the Safety and Efficacy of SAL0120 in Patients With Chronic Kidney Disease (CKD)

NCT02780726Completed

A Study of Intermittent Oral Dosing of ASP1517 in Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia